A Phase 2B Randomized Double Blind Placebo Controlled Study to Evaluate the Safety and Efficacy of JVS-100 Administered by Direct Intramuscular Injection as Adjunct to Revascularization of Infrapopliteal Lesions in Subjects With Advanced Peripheral Artery Disease and Tissue Loss

Trial Profile

A Phase 2B Randomized Double Blind Placebo Controlled Study to Evaluate the Safety and Efficacy of JVS-100 Administered by Direct Intramuscular Injection as Adjunct to Revascularization of Infrapopliteal Lesions in Subjects With Advanced Peripheral Artery Disease and Tissue Loss

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2016

At a glance

  • Drugs JVS 100 (Primary)
  • Indications Peripheral arterial disorders
  • Focus Therapeutic Use
  • Acronyms STOP-PAD
  • Sponsors Juventas Therapeutics
  • Most Recent Events

    • 04 Feb 2016 According to a Juventas therapeutics media release, first patient is enrolled in the phase II study of JVS-100 for the of Advanced Peripheral Artery Disease
    • 08 Dec 2015 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
    • 12 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top